
Pooled Review Finds No Benefit, More Bleeding With Distal Clot Removal
Key Takeaways
- Three RCTs (DISTAL, ESCAPE-MeVO, interim DISCOUNT) showed no efficacy signal for thrombectomy on primary disability outcomes in MeVO/DiVO populations, including neutral ordinal mRS shifts and no gain in mRS 0–2.
- Pooled estimates demonstrated no improvement in 90-day functional independence (RR 0.92) but a significant increase in symptomatic intracranial hemorrhage (OR 2.38) with thrombectomy versus medical therapy alone.
Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.
A systematic review and pooled analysis of 3 randomized trials found that mechanical thrombectomy did not improve functional independence after medium or distal vessel occlusion stroke, while significantly increasing the risk of symptomatic intracranial hemorrhage. Researchers presented the findings as a poster at the
Shradha P. Kakde, MBBS, a research scholar at Albany Medical Center, led the review with Meghnath P. Kakde, MBBS, and Shubhangi P. Kakade, MBBS, of Smt. Kashibai Navale Medical College and General Hospital in Pune, India. The investigators searched PubMed, Embase, and the Cochrane Library through January 2026 for randomized trials comparing thrombectomy plus medical therapy with medical therapy alone in medium or distal vessel occlusion stroke, following PRISMA 2020 guidance and assessing risk of bias with the Cochrane RoB 2 tool.
The review prioritized 90-day functional independence, a modified Rankin Scale (mRS) score of 0 to 2, and also examined excellent outcome (mRS 0-1), symptomatic intracranial hemorrhage, and mortality.
Three randomized trials met criteria: DISTAL, which enrolled 543 patients treated within 24 hours; ESCAPE-MeVO, which enrolled 530 patients treated within 12 hours; and an interim analysis of DISCOUNT, which enrolled 163 patients treated within 8 hours, or up to 24 hours if fluid-attenuated inversion recovery (FLAIR) imaging was negative. All 3 trials compared thrombectomy plus medical therapy against medical therapy alone in patients with medium or distal vessel occlusions.1-4
On each trial's own primary endpoint, results ran neutral to negative for thrombectomy. DISTAL found no shift toward better outcomes on the ordinal mRS scale (common odds ratio [OR], 0.90; 95% CI, 0.67-1.22).[1] ESCAPE-MeVO found no difference in excellent outcome, mRS 0-1 (41.6% vs 43.1%; adjusted relative risk [RR], 0.95; 95% CI, 0.79-1.15).2 The interim DISCOUNT analysis found a lower rate of functional independence, mRS 0-2, with thrombectomy than with medical therapy alone (60% vs 77%).4
A separate 3-trial meta-analysis incorporating the interim DISCOUNT data found no significant difference in functional independence (RR, 0.92; 95% CI, 0.80-1.06; I2=52%), but a significantly higher rate of symptomatic intracranial hemorrhage with thrombectomy (OR, 2.38; 95% CI, 1.35-4.20).4 Mortality did not differ significantly in the pooled analysis (OR, 1.23; 95% CI, 0.76-1.99), and the investigators noted that an adjusted mortality signal seen in ESCAPE-MeVO alone (13.3% vs 8.4%; adjusted hazard ratio, 1.82; 95% CI, 1.06-3.12) was not confirmed once the trials were pooled.2,4
Symptomatic intracranial hemorrhage was numerically higher with thrombectomy than with medical therapy alone in all 3 trials: 5.9% versus 2.6% in DISTAL, 5.4% versus 2.2% in ESCAPE-MeVO, and 11% versus 3% in the final, as-treated DISCOUNT safety analysis, though the investigators cautioned that safety analysis populations differed across trials.1-3
Occlusion location, deficit severity, and time to treatment varied across the 3 trials, complicating any single conclusion about who might benefit.1-3 A post hoc estimate of benefit in proximal M2 occlusions (adjusted OR, 2.68; 95% CI, 1.13-6.37) came from an earlier subgroup analysis of the HERMES collaboration, a pooled analysis of large-vessel thrombectomy trials, while an early, inconclusive ESCAPE-MeVO signal suggested possible benefit when treatment began within fewer than 260 minutes of stroke onset.5,6
The investigators flagged 2 studies published after their January 2026 search cutoff. The final report of DISCOUNT, now encompassing 244 patients, found functional independence in 62% of thrombectomy-treated patients versus 68% on medical therapy alone, a nonsignificant difference (OR, 0.73; 95% CI, 0.40-1.31; P=.29), while symptomatic intracranial hemorrhage remained more common with thrombectomy (11% vs 3%).[3] A separate trial, ORIENTAL-MeVO, enrolled patients with a baseline NIH Stroke Scale score of 6 or higher, a more severely affected population than the other 3 trials, and found a numerically higher rate of favorable outcome with thrombectomy (58.6% vs 46.6%).7
The authors concluded that the 3 trials in their review did not support routine thrombectomy for medium or distal vessel occlusion stroke and showed more symptomatic bleeding with the procedure. They framed the open question as which patients might still benefit, writing that later evidence makes deficit severity and occlusion anatomy central to that discussion.1
Testing whether a proven therapy extends to smaller vessels
Thrombectomy transformed the treatment of large-vessel occlusion stroke after trials published in 2015 demonstrated a substantial functional benefit, leading researchers to ask whether occlusions in smaller, more distal arteries, which make up a sizable share of ischemic strokes but were excluded from those earlier trials, might benefit similarly.[6] DISTAL and ESCAPE-MeVO, both
For more SVIN 2026 coverage,
References
1. Psychogios M, Brehm A, Ribo M, et al. Endovascular treatment for stroke due to occlusion of medium or distal vessels. N Engl J Med. 2025;392(14):1374-1384. doi:10.1056/NEJMoa2408954
2. Goyal M, Ospel JM, Ganesh A, et al. Endovascular treatment of stroke due to medium-vessel occlusion. N Engl J Med. 2025;392(14):1385-1395. doi:10.1056/NEJMoa2411668
3. Clarençon F, Bala F, Baptiste A, et al. Mechanical thrombectomy in ischemic stroke with a medium or distal arterial occlusion: the DISCOUNT randomized clinical trial. JAMA. 2026;336(9):755-764. doi:10.1001/jama.2026.8977
4. Schellinger PD, Tsivgoulis G, Frank B, Liebig T, Köhrmann M. Randomized controlled trials of endovascular therapy for acute ischemic stroke with medium or distal vessel occlusion: a study level meta-analysis. Neurol Res Pract. 2025;7(1). doi:10.1186/s42466-025-00400-4
5. Society of Vascular and Interventional Neurology. SVIN focused practice guideline on medium and distal vessel occlusion thrombectomy. 2026.
6. Diprose WK, Pensato U, Almekhlafi M, et al. Acute management of medium vessel occlusion stroke: new evidence and a path forward. Stroke. 2026;57(3):814-828. doi:10.1161/STROKEAHA.125.050401
7. Hu W, Jing X, Chen Z, et al. Endovascular treatment of medium-vessel-occlusion strokes. N Engl J Med. 2026;394(19):1894-1904. doi:10.1056/NEJMoa2514120
Related to this article








